Coherus Oncology Inc CHRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.03
- Day Range
- $1.00–1.08
- 52-Week Range
- $0.97–2.62
- Bid/Ask
- $1.05 / $1.07
- Shares Outstanding
- 154.50M
- Market Cap
- $165.32M
- Volume/Avg
- 452 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 144
- Website
- https://www.coherus.com
Valuation
|
Metric
|
CHRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.72 |
Price/Sales | 2.77 |
Price/Cash Flow | — |
Price/Earnings
CHRS
Financial Strength
|
Metric
|
CHRS
|
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 1.74 |
Interest Coverage | −16.74 |
Quick Ratio
CHRS
Profitability
|
Metric
|
CHRS
|
|---|---|
Return on Assets (Normalized) | −42.89% |
Return on Equity (Normalized) | −175.68% |
Return on Invested Capital (Normalized) | −110.12% |
Return on Assets
CHRS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Fc^#! | LOCK|lj^s | $123B | |||
| Moderna Inc
MRNA
| LOCK|&Y?<M% | LOCK|bN | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@R$r!X@ | LOCK|Pq&l | $78B | |||
| argenx SE ADR
ARGX
| LOCK|vC%?J%! | LOCK|GTX | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^G%Zjl& | LOCK|%n | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Hy>VMc | LOCK|R#$> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|t^#B?w& | LOCK|&v%>J | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|<<^rM$ | LOCK|pts | $22B | |||
| Incyte Corp
INCY
| LOCK|%jNg&R | LOCK|?q# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|t?!K>@j | LOCK|Np$ | $14B |
United States